Alpha Tau Medical (NASDAQ:DRTS) Price Target Lowered to $7.00 at Citigroup

Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by Citigroup from $8.00 to $7.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Alpha Tau Medical in a research report on Wednesday. Finally, Wall Street Zen upgraded Alpha Tau Medical to a “sell” rating in a report on Saturday, November 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Alpha Tau Medical presently has an average rating of “Hold” and an average price target of $8.00.

Alpha Tau Medical Trading Up 19.6%

Alpha Tau Medical stock opened at $5.06 on Wednesday. Alpha Tau Medical has a 12 month low of $2.30 and a 12 month high of $5.07. The company has a quick ratio of 5.81, a current ratio of 8.43 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average price of $3.97 and a two-hundred day moving average price of $3.53. The stock has a market cap of $429.19 million, a price-to-earnings ratio of -9.73 and a beta of 1.06.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Thursday, November 20th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, equities analysts forecast that Alpha Tau Medical will post -0.45 EPS for the current year.

Institutional Trading of Alpha Tau Medical

A number of large investors have recently added to or reduced their stakes in the company. Kovitz Investment Group Partners LLC boosted its stake in shares of Alpha Tau Medical by 601.4% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company’s stock worth $568,000 after acquiring an additional 194,055 shares during the period. Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 6.3% in the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after buying an additional 12,200 shares in the last quarter. Mariner LLC grew its stake in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares in the last quarter. Millennium Management LLC acquired a new stake in Alpha Tau Medical in the 3rd quarter worth about $170,000. Finally, Bank of America Corp DE boosted its holdings in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.